Quantum Biopharma (NASDAQ:QNTM) Releases Earnings Results

Quantum Biopharma (NASDAQ:QNTM) issued its earnings results on Friday. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.05), Zacks reports.

Quantum Biopharma Trading Up 3.7%

Quantum Biopharma stock opened at $8.91 on Friday. Quantum Biopharma has a 52 week low of $2.70 and a 52 week high of $38.25. The stock has a market cap of $34.04 million, a P/E ratio of -0.82 and a beta of 0.54. The stock has a 50 day moving average of $15.04 and a 200-day moving average of $16.71.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen lowered Quantum Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.